AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca has sealed a $39 billion deal to ... Read More
Alexion to acquire Achillion to strengthen rare diseases portfolio
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal ... Read More
Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria
Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of ... Read More